Repetitive Transcranial Magnetic Stimulation (rTMS) for Schizophrenia
Study Summary
This trial is an extension of a previous study investigating the efficacy of transcranial magnetic stimulation (TMS) on patients with schizophrenia. The extension study will further assess the safety and efficacy of TMS on these patients. Patients who have completed the 4-week project #8116 can be screened for eligibility for this extension study in which they will continue treatment/assessment.
- Schizophrenia
Treatment Effectiveness
Effectiveness Progress
Study Objectives
3 Primary · 7 Secondary · Reporting Duration: Up to 4/8 weeks.
Trial Safety
Safety Progress
Trial Design
3 Treatment Groups
Complete responders undergo four follow-up clinical assessments
1 of 3
Partial responders undergo rTMS of the left temporo-parietal junction (TPJ)
1 of 3
Non-responders undergo rTMS of the right superior temporal sulcus (STS)
1 of 3
Active Control
Experimental Treatment
12 Total Participants · 3 Treatment Groups
Primary Treatment: Repetitive Transcranial Magnetic Stimulation (rTMS) · No Placebo Group · N/A
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 22 - 55 · All Participants · 12 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Is the trial still open for enrollment?
"Correct. As of the most recent update on September 15, 2022, this clinical trial is still open and actively recruiting participants. This research project was initially posted online with a start date of September 12th 2022." - Anonymous Online Contributor
What is the participant recruitment rate for this research endeavor?
"Affirmative. According to information available on clinicaltrials.gov, this medical trial, first posted on 12th September 2022 is seeking enrolment from 12 individuals at a single location. The study was last updated on the 15th of September that same year." - Anonymous Online Contributor
What is the goal of this experiment?
"This medical trial will have an 8-week assessment period, during which the primary outcome of interest is the total number of adverse events that occur. Additionally, changes in Clinical Global Impression Improvement (CGI-I) Scale, Psychotic Symptom Rating Scale (PSYRATS), and Clinical Global Impression Severity (CGI-S) Scale scores are also examined as secondary outcomes. These scales measure overall illness improvement or severity on a 7 point scale ranging from 1 to 7 respectively." - Anonymous Online Contributor
Is this research project accessible to those under the age of fifty?
"As stated in the criteria for participation, this clinical trial has a lower age limit of 22 and an upper age limit of 55." - Anonymous Online Contributor
Can I qualify for the experiment?
"This research project is recruiting twelve individuals between 22 and 55 years of age with behavioral disorders. To be accepted, they must fulfill the following requirements: having completed study #8116 (NCT05319080), DSM-V diagnosis of schizophrenia or schizoaffective disorder, a Reduction in AHRS lower than 50% at baseline, capacity to provide informed consent for participation and willingness to comply with contraception protocols if female and not infertile; have negative pregnancy test results if applicable; right handedness; normal hearing levels; taking an antipsychotic medication at stable dose for 4 weeks minimum. All oral and depot drugs are permitted." - Anonymous Online Contributor